BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24973208)

  • 21. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
    Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
    Clerc P; Carey GB; Mehrabian Z; Wei M; Hwang H; Girnun GD; Chen H; Martin SS; Polster BM
    PLoS One; 2012; 7(8):e42487. PubMed ID: 22880001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drp1 is dispensable for apoptotic cytochrome c release in primed MCF10A and fibroblast cells but affects Bcl-2 antagonist-induced respiratory changes.
    Clerc P; Ge SX; Hwang H; Waddell J; Roelofs BA; Karbowski M; Sesaki H; Polster BM
    Br J Pharmacol; 2014 Apr; 171(8):1988-99. PubMed ID: 24206264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
    Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK; Deng X
    Theranostics; 2021; 11(17):8500-8516. PubMed ID: 34373755
    [No Abstract]   [Full Text] [Related]  

  • 26. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.
    Pallis M; Burrows F; Ryan J; Grundy M; Seedhouse C; Abdul-Aziz A; Montero J; Letai A; Russell N
    Oncotarget; 2017 Mar; 8(10):16220-16232. PubMed ID: 27092880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Bhatt S; Pioso MS; Olesinski EA; Yilma B; Ryan JA; Mashaka T; Leutz B; Adamia S; Zhu H; Kuang Y; Mogili A; Louissaint A; Bohl SR; Kim AS; Mehta AK; Sanghavi S; Wang Y; Morris E; Halilovic E; Paweletz CP; Weinstock DM; Garcia JS; Letai A
    Cancer Cell; 2020 Dec; 38(6):872-890.e6. PubMed ID: 33217342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199.
    García CP; Videla Richardson GA; Dimopoulos NA; Fernandez Espinosa DD; Miriuka SG; Sevlever GE; Romorini L; Scassa ME
    PLoS One; 2016; 11(3):e0152607. PubMed ID: 27030982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
    Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
    Biomed Pharmacother; 2024 Jun; 175():116719. PubMed ID: 38749173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
    Renault TT; Elkholi R; Bharti A; Chipuk JE
    J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study.
    Rohner L; Reinhart R; Iype J; Bachmann S; Kaufmann T; Fux M
    Sci Rep; 2020 Jan; 10(1):222. PubMed ID: 31937836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
    Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
    Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the BH3-only protein Puma as a direct Bak activator.
    Dai H; Pang YP; Ramirez-Alvarado M; Kaufmann SH
    J Biol Chem; 2014 Jan; 289(1):89-99. PubMed ID: 24265320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
    Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.
    Zhang Z; Lai GH; Sirica AE
    Hepatology; 2004 Apr; 39(4):1028-37. PubMed ID: 15057907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
    Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
    Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.